{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T06:42:31Z","timestamp":1794724951888,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T00:00:00Z","timestamp":1692057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T00:00:00Z","timestamp":1692057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple myeloma received subcutaneous elranatamab once weekly after two step-up priming doses. After six cycles, persistent responders switched to biweekly dosing. Results from cohort A, which enrolled patients without prior BCMA-directed therapy (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009123) are reported. The primary endpoint of confirmed objective response rate (ORR) by blinded independent central review was met with an ORR of 61.0% (75\/123); 35.0% \u2265complete response. Fifty responders switched to biweekly dosing, and 40 (80.0%) improved or maintained their response for \u22656\u2009months. With a median follow-up of 14.7\u2009months, median duration of response, progression-free survival and overall survival (secondary endpoints) have not been reached. Fifteen-month rates were 71.5%, 50.9% and 56.7%, respectively. Common adverse events (any grade; grade 3\u20134) included infections (69.9%, 39.8%), cytokine release syndrome (57.7%, 0%), anemia (48.8%, 37.4%), and neutropenia (48.8%, 48.8%). With biweekly dosing, grade 3\u20134 adverse events decreased from 58.6% to 46.6%. Elranatamab induced deep and durable responses with a manageable safety profile. Switching to biweekly dosing may improve long-term safety without compromising efficacy. ClinicalTrials.gov identifier:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT04649359\" ext-link-type=\"uri\">NCT04649359<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-023-02528-9","type":"journal-article","created":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T12:01:42Z","timestamp":1692100902000},"page":"2259-2267","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":684,"title":["Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9321-702X","authenticated-orcid":false,"given":"Alexander M.","family":"Lesokhin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Tomasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Arnulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-7034","authenticated-orcid":false,"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0058-2448","authenticated-orcid":false,"given":"H.","family":"Miles Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Niesvizky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Rodr\u03afguez-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7908-0063","authenticated-orcid":false,"given":"Joaquin","family":"Martinez-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guenther","family":"Koehne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Jethava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Depaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisayuki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin Eli","family":"Gabayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don A.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4165-6869","authenticated-orcid":false,"given":"Ajay K.","family":"Nooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur","family":"Raje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4181-6922","authenticated-orcid":false,"given":"Marc-Steffen","family":"Raab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Searle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Leip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon T.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elmeliegy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akos","family":"Czibere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Viqueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,15]]},"reference":[{"key":"2528_CR1","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"MV Mateos","year":"2022","unstructured":"Mateos, M. V. et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia 36, 1371\u20131376 (2022).","journal-title":"Leukemia"},{"key":"2528_CR2","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1182\/hematology.2022000396","volume":"2022","author":"P Rodriguez-Otero","year":"2022","unstructured":"Rodriguez-Otero, P. & San-Miguel, J. F. Cellular therapy for multiple myeloma: what\u2019s now and what\u2019s next. Hematol. Am. Soc. Hematol. Educ. Program 2022, 180\u2013189 (2022).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"2528_CR3","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah, N., Chari, A., Scott, E., Mezzi, K. & Usmani, S. Z. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 34, 985\u20131005 (2020).","journal-title":"Leukemia"},{"key":"2528_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495\u2013505 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2528_CR5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2528_CR6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"2528_CR7","unstructured":"Celgene Corporation, a Bristol-Myers Squibb Company. ABECMA\u00ae (idecabtagene vicleucel) prescribing information. https:\/\/www.fda.gov\/media\/147055\/download (2021)."},{"key":"2528_CR8","unstructured":"Janssen Biotech, Inc. CARVYKTI\u00ae (ciltacabtagene autoleucel) prescribing information. https:\/\/www.fda.gov\/media\/156560\/download (2022)."},{"key":"2528_CR9","unstructured":"Janssen Biotech, Inc. TECVAYLI\u2122 (teclistamab-cqyv) prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761291s000lbl.pdf (2022)."},{"key":"2528_CR10","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1158\/1535-7163.MCT-19-0007","volume":"18","author":"SH Panowski","year":"2019","unstructured":"Panowski, S. H. et al. Preclinical efficacy and safety comparison of CD3 bispecific and ADC modalities targeting BCMA for the treatment of multiple myeloma. Mol. Cancer Ther. 18, 2008\u20132020 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"2528_CR11","doi-asserted-by":"publisher","first-page":"8006","DOI":"10.1200\/JCO.2021.39.15_suppl.8006","volume":"39","author":"JB Nizar","year":"2021","unstructured":"Nizar, J. B. et al. Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM). J. Clin. Oncol. 39, 8006 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2528_CR12","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1182\/blood-2021-150519","volume":"138","author":"M Sebag","year":"2021","unstructured":"Sebag, M. et al. Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: results from MagnetisMM-1. Blood 138, 895 (2021).","journal-title":"Blood"},{"key":"2528_CR13","doi-asserted-by":"publisher","first-page":"8014","DOI":"10.1200\/JCO.2022.40.16_suppl.8014","volume":"40","author":"JJ Andrzej","year":"2022","unstructured":"Andrzej, J. J. et al. Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: updated results from MagnetisMM-1. J. Clin. Oncol. 40, 8014 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2528_CR14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1182\/blood-2022-166494","volume":"140","author":"N Raje","year":"2022","unstructured":"Raje, N. et al. Elranatamab, a BCMA targeted T-cell engaging bispecific antibody, induces durable clinical and molecular responses for patients with relapsed or refractory multiple myeloma. Blood 140, 388\u2013390 (2022).","journal-title":"Blood"},{"key":"2528_CR15","doi-asserted-by":"publisher","first-page":"8006","DOI":"10.1200\/JCO.2022.40.16_suppl.8006","volume":"40","author":"AM Lesokhin","year":"2022","unstructured":"Lesokhin, A. M. et al. Initial safety results for MagnetisMM-3: a phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed\/refractory (R\/R) multiple myeloma (MM). J. Clin. Oncol. 40, 8006 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2528_CR16","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1182\/blood-2021-152984","volume":"138","author":"A Lesokhin","year":"2021","unstructured":"Lesokhin, A. et al. Magnetismm-3: an open-label, multicenter, non-randomized phase 2 study of elranatamab (PF-06863135) in patients with relapsed or refractory multiple myeloma. Blood 138, 1674 (2021).","journal-title":"Blood"},{"key":"2528_CR17","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet Oncol."},{"key":"2528_CR18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"2528_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial, S. et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 21, 207\u2013221 (2020).","journal-title":"Lancet Oncol."},{"key":"2528_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00643-3","volume":"12","author":"J Blade","year":"2022","unstructured":"Blade, J. et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 12, 45 (2022).","journal-title":"Blood Cancer J."},{"key":"2528_CR21","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo, A. et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J. Clin. Oncol. 33, 2863\u20132869 (2015).","journal-title":"J. Clin. Oncol."},{"key":"2528_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00733-2","volume":"12","author":"SK Gill","year":"2022","unstructured":"Gill, S. K. et al. I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients. Blood Cancer J. 12, 138 (2022).","journal-title":"Blood Cancer J."},{"key":"2528_CR23","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1002\/cncr.33809","volume":"127","author":"S Lonial","year":"2021","unstructured":"Lonial, S. et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer 127, 4198\u20134212 (2021).","journal-title":"Cancer"},{"key":"2528_CR24","doi-asserted-by":"publisher","first-page":"8011","DOI":"10.1200\/JCO.2023.41.16_suppl.8011","volume":"41","author":"NWCJ Donk de van","year":"2023","unstructured":"Donk de van, N. W. C. J. et al. Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM). J. Clin. Oncol. 41, 8011 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2528_CR25","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin, T. et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J. Clin. Oncol. 41, 1265\u20131274 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2528_CR26","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari, A. et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N. Engl. J. Med. 387, 2232\u20132244 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2528_CR27","unstructured":"GlaxoSmithKline, Ltd. BLENREP (belantamab mafodotin-blmf) prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761158s000lbl.pdf (2020)."},{"key":"2528_CR28","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson, P. G. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609\u20132617 (2003).","journal-title":"N. Engl. J. Med."},{"key":"2528_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1586\/14737140.1.1.20","volume":"1","author":"SV Rajkumar","year":"2001","unstructured":"Rajkumar, S. V. Thalidomide in the treatment of multiple myeloma. Expert Rev. Anticancer Ther. 1, 20\u201328 (2001).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"2528_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00808-8","volume":"13","author":"BZ Sim","year":"2023","unstructured":"Sim, B. Z. et al. Infectious complications of bispecific antibody therapy in patients with multiple myeloma. Blood Cancer J. 13, 34 (2023).","journal-title":"Blood Cancer J."},{"key":"2528_CR31","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","volume":"7","author":"F Mazahreh","year":"2023","unstructured":"Mazahreh, F. et al. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 7, 3069\u20133074 (2023).","journal-title":"Blood Adv."},{"key":"2528_CR32","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","volume":"6","author":"S Kambhampati","year":"2022","unstructured":"Kambhampati, S. et al. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 6, 2045\u20132054 (2022).","journal-title":"Blood Adv."},{"key":"2528_CR33","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.1182\/bloodadvances.2021004896","volume":"5","author":"L Mikkilineni","year":"2021","unstructured":"Mikkilineni, L. et al. Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days. Blood Adv. 5, 5312\u20135322 (2021).","journal-title":"Blood Adv."},{"key":"2528_CR34","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1182\/bloodadvances.2021006178","volume":"6","author":"M Mohan","year":"2022","unstructured":"Mohan, M. et al. Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. Blood Adv. 6, 2466\u20132470 (2022).","journal-title":"Blood Adv."},{"key":"2528_CR35","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1200\/JCO.22.01504","volume":"40","author":"A D\u2019Souza","year":"2022","unstructured":"D\u2019Souza, A. et al. A phase I first-in-human study of ABBV-383, a B-cell maturation antigen x CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma. J. Clin. Oncol. 40, 3576\u20133586 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2528_CR36","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","volume":"9","author":"NS Raje","year":"2022","unstructured":"Raje, N. S. et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 9, e143\u2013e161 (2022).","journal-title":"Lancet Haematol."},{"key":"2528_CR37","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","volume":"24","author":"H Ludwig","year":"2023","unstructured":"Ludwig, H. et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 24, e255\u2013e269 (2023).","journal-title":"Lancet Oncol."},{"key":"2528_CR38","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/s41375-023-01920-1","volume":"37","author":"E Terpos","year":"2023","unstructured":"Terpos, E. et al. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN). Leukemia 37, 1175\u20131185 (2023).","journal-title":"Leukemia"},{"key":"2528_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00879-7","volume":"13","author":"NA Raje","year":"2023","unstructured":"Raje, N. A. et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving 1 bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 13, 116 (2023).","journal-title":"Blood Cancer J."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02528-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02528-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02528-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T19:01:44Z","timestamp":1783710104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02528-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,15]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["2528"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02528-9","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,15]]},"assertion":[{"value":"18 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.M.L. reports consulting or advisory roles for Pfizer, Trillium Therapeutics and Arcellx; personal fees from ITeos Therapeutics, Janssen, Legend Biotech, Pfizer, Sanofi and Trillium Therapeutics; institutional research support from Bristol-Myers Squibb, Genentech, Janssen Oncology, Pfizer, Sanofi, Trillium Therapeutics and patents, royalties and\/or other intellectual property interests with Serametrix. M.H.T. reports consulting or advisory roles for Janssen. G.K., Y.J., A.E.G. and D.A.S. have no competing interests to report. B.A. reports consulting or advisory roles for Amgen, Celgene, Janssen-Cilag and Sanofi; personal fees from Celgene, Janssen-Cilag, Sanofi and Takeda; research support from Janssen-Cilag and travel and accommodations expenses paid for by Amgen, Celgene, Janssen-Cilag and Takeda. N.J.B. reports consulting or advisory roles for Amgen, Celgene, Janssen, Karyopharm Therapeutics, Pfizer, Sanofi and Takeda; personal fees from AbbVie, Amgen, Celgene, Genentech\/Roche, GSK, Janssen, Karyopharm Therapeutics, Sanofi and Takeda and patents, royalties, and\/or other intellectual property interests with Celgene and Janssen. H.M.P. reports consulting or advisory roles for Bristo-Myers Squibb, GSK, Janssen, Takeda and Sanofi and research support from AbbVie and Bristol-Myers Squibb. R.N. reports consulting or advisory roles for Bristol-Myers Squibb, GSK, Janssen, Karyopharm Therapeutics and Takeda and research support from Bristol-Myers Squibb, GSK, Janssen, Karyopharm Therapeutics and Takeda. P.R.O. reports consulting or advisory roles for AbbVie, Bristol-Myers Squibb, GSK, Janssen, Pfizer and Sanofi; personal fees from AbbVie, Celgene, GSK, H3 Biomedicine, Janssen, Pfizer and Sanofi; travel and accommodations expenses paid for by Pfizer and speaker\u2019s bureau roles with Bristol-Myers Squibb, GSK, Janssen and Sanofi. J.M.L. reports consulting or advisory roles for Bristol-Myers Squibb, Janssen Oncology and Novartis; institutional research support from Astellas Pharma and Bristol-Myers Squibb and speaker\u2019s bureau roles with Bristol-Myers Squibb, Janssen-Cilag and Roche. C.T. reports consulting or advisory roles for AbbVie, Amgen, Celgene, GSK, Janssen, Novartis and Takeda; personal fees from AbbVie, Amgen, Celgene, GSK, Janssen, Novartis, Sanofi and Takeda; research support from AbbVie, GSK and Sanofi and travel and accommodations expenses paid for by Pfizer and Janssen. H.Q. reports consulting or advisory roles for Amgen, Antengene, Bristol-Myers Squibb\/Celgene, Celgene, CSL Behring, GSK, Janssen-Cilag, Karyopharm Therapeutics, Pfizer, Roche and Sanofi and research support from Amgen, Bristol-Myers Squibb\/Celgene, Celgene, GSK, Karyopharm Therapeutics and Sanofi. J.D. reports a consulting or advisory role for Novartis and travel and accommodations expenses paid for by AstraZeneca Spain. H.Y. reports research support from Astellas Pharma. A.K.N. reports consulting or advisory roles for Adaptive Biotechnologies, Amgen, BeyondSpring Pharmaceuticals, Bristol-Myers Squibb, Cellectar, Genzyme, GSK, Janssen Oncology, Karyopharm Therapeutics, Oncopeptides, ONK Therapeutics, Pfizer, Secura Bio and Takeda; personal fees from Adaptive Biotechnologies, Amgen, BeyondSpring Pharmaceuticals, Bristol-Myers Squibb\/Celgene, Cellectar, Genzyme, GSK, Janssen Oncology, Karyopharm Therapeutics, Oncopeptides, ONK Therapeutics, Pfizer, Secura Bio and Takeda; institutional research support from Amgen, Arch Oncology, Bristol-Myers Squibb\/Celgene, Cellectar, GSK, Janssen Oncology, Pfizer and Takeda and travel and accommodations expenses paid for by GSK. S.M. reports consulting or advisory roles for AbbVie, Adaptive Biotechnologies, Amgen, Bristol-Myers Squibb\/Celgene, GSK, Janssen, Regeneron, Roche, Sanofi and Takeda. N.R. reports consulting or advisory roles for Amgen, Bristol-Myers Squibb, Celgene, GSK, Janssen, Merck and Takeda; personal fees from Medscape and Research To Practice and research support from 2Seventy Bio. S.I. reports consulting or advisory roles for Janssen, Sanofi, Takeda, Pfizer, Novartis, Bristol-Myers Squibb and AbbVie; personal fees from Bristol-Myers Squibb, Celgene, Janssen, Ono Pharmaceutical, Pfizer, Sanofi, and Takeda and research support from AbbVie, Amgen, Bristol-Myers Squibb, Caelum Biosciences, Celgene, Daiichi Sankyo Pharmaceutical, Janssen, Ono Pharmaceutical, Otsuka, Sanofi, Shionogi and Takeda. M.S.R. reports consulting or advisory roles for Amgen, Bristol-Myers Squibb, GSK, Janssen, Oncopeptides, Pfizer and Sanofi; personal fees from AbbVie, Bristol-Myers Squibb, GSK and Takeda and research support from Bristol-Myers Squibb, Janssen, Novartis and Sanofi. E.S. reports consulting or advisory roles for Shattuck Labs and Sanofi; personal fees from AbbVie, Janssen and travel and accommodations expenses paid for by Janssen. E.L., S.T.S., U.C., M.E., A.C. and A.V. report employment and stock ownership at Pfizer. M.M. reports consulting or advisory roles for Adaptive Biotechnologies, GSK, Jazz Pharmaceuticals, MaaT Pharma, Novartis, Sanofi and Xenikos; personal fees from Amgen, Astellas, Bristol-Myers Squibb, Celgene, Pfizer, Stemline-Menarini and Takeda and speaker\u2019s bureau roles with Janssen, Jazz Pharmaceuticals and Sanofi.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}